查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1991564

2026-2034年全球血漿衍生蛋白療法市場規模、佔有率、趨勢和成長分析報告

Global Plasma-Derived Protein Therapies Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計血漿衍生蛋白療法市場將從 2025 年的 392.7 億美元成長到 2034 年的 701.6 億美元，2026 年至 2034 年的複合年成長率為 6.66%。

由於需要特殊治療的罕見疾病和慢性病盛行率不斷上升，全球血漿衍生蛋白療法市場正經歷顯著成長。血漿衍生蛋白療法可用於治療多種疾病，包括免疫力缺乏、出血性疾病和神經系統疾病。對有效生物製藥日益成長的需求正在推動全球血漿採集和處理設施的擴張。

推動該市場成長的因素包括血漿分餾技術的進步和生物製藥研發投入的增加。人們對罕見疾病的認知不斷提高以及診斷能力的提升也促進了治療方法的普及。此外，血漿捐獻中心的擴建有助於確保生產這些治療藥物所需原料的穩定供應。

未來，隨著新的治療應用不斷湧現，血漿衍生蛋白療法市場預計將進一步擴張。免疫學和神經學領域的持續研究有望為血漿治療方法帶來新的機會。隨著醫療保健支出不斷成長以及先進療法的普及，預計該市場將在全球範圍內持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球血漿衍生蛋白治療市場：依產品分類

  • 市場分析、洞察與預測
  • 白蛋白
  • 免疫球蛋白
  • 血漿衍生因子VIII
  • 其他

第5章 全球血漿衍生蛋白治療市場：依應用領域分類

  • 市場分析、洞察與預測
  • 血友病
  • 原發性免疫力缺乏（PIDD）
  • 特發性血小板減少紫斑症（ITP）
  • 其他

第6章 全球血漿衍生蛋白治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Bio Products Laboratory Ltd
    • Octapharma AG
    • CSL Limited
    • Grifols, SA
    • Taibang Biological Group Co., Ltd
    • Takeda Pharmaceutical Company Limited
    • ADMA Biologics Inc
    • Bayer AG
    • Baxter International Inc
    • Kedrion, SpA
    • Biotest AG
簡介目錄
Product Code: VMR11214327

The Plasma-Derived Protein Therapies Market size is expected to reach USD 70.16 Billion in 2034 from USD 39.27 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The global plasma-derived protein therapies market is witnessing significant growth due to the increasing prevalence of rare and chronic diseases that require specialized treatment. Plasma-derived protein therapies are used to treat a variety of medical conditions, including immune deficiencies, bleeding disorders, and neurological diseases. The growing demand for effective biologic treatments is driving the expansion of plasma collection and processing facilities worldwide.

Several factors are fueling the growth of this market, including advancements in plasma fractionation technologies and rising investments in biopharmaceutical research. Increased awareness about rare diseases and improved diagnostic capabilities are also contributing to higher treatment adoption rates. Additionally, the expansion of plasma donation centers is helping to ensure a stable supply of raw materials for the production of these therapies.

In the future, the plasma-derived protein therapies market is expected to expand further as new therapeutic applications continue to emerge. Ongoing research in immunology and neurology is likely to create new opportunities for plasma-based treatments. With increasing healthcare expenditure and expanding access to advanced therapies, the market is poised for sustained growth globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

  • Albumin
  • Immunoglobulin
  • Plasma-derived Factor VIII
  • Others

By Application

  • Hemophilia
  • Primary Immunodeficiency Disorder (PIDD)
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Others

COMPANIES PROFILED

  • Bio Products Laboratory Ltd, Octapharma AG, CSL Limited, Grifols, SA, Taibang Biological Group Co, Ltd, Takeda Pharmaceutical Company Limited, ADMA Biologics Inc, Bayer AG, Baxter International Inc, Kedrion, SpA, Biotest AG
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA-DERIVED PROTEIN THERAPIES MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Immunoglobulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Plasma-derived Factor VIII Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA-DERIVED PROTEIN THERAPIES MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Hemophilia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Primary Immunodeficiency Disorder (PIDD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Idiopathic Thrombocytopenic Purpura (ITP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA-DERIVED PROTEIN THERAPIES MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Product
    • 6.2.2 By Application
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Product
    • 6.3.2 By Application
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Product
    • 6.4.2 By Application
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Product
    • 6.5.2 By Application
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Product
    • 6.6.2 By Application
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PLASMA-DERIVED PROTEIN THERAPIES INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Bio Products Laboratory Ltd
    • 8.2.2 Octapharma AG
    • 8.2.3 CSL Limited
    • 8.2.4 Grifols, S.A
    • 8.2.5 Taibang Biological Group Co., Ltd
    • 8.2.6 Takeda Pharmaceutical Company Limited
    • 8.2.7 ADMA Biologics Inc
    • 8.2.8 Bayer AG
    • 8.2.9 Baxter International Inc
    • 8.2.10 Kedrion, SpA
    • 8.2.11 Biotest AG